[Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
We compared efficacy of conventional myelosuppressive chemotherapy with myelosan, hydrealitalir and interferon-alpha (Ifn-a) therapy in 52 patients with chronic myeloid leukemia (CML). The latter treatment (Ifn-a was given in different doses) was conducted in 23 patients. Significant differences (p = 0.007) were found in medians of survival of patients on conventional myelosuppressive chemotherapy (40 months) and on Ifn-a therapy (61 months). Toxicity of treatment with Ifn-a (domestic reaferon, in particular) was mild. Thus, Ifn-a treatment was more effective than conventional myelosuppressive therapy against CML in a chronic phase.
Volkova
S A
SA
Prytkova
M V
MV
Borovkov
N N
NN
D000328:Adult; D000368:Aged; D002066:Busulfan / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D002066:Busulfan